Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7404539 | 0.87 | ACHE (0.46) | EPHX1ACHEALDH1A1 | |
| SCHEMBL1161276 | 0.85 | CTSK (0.45) | EPHX1CYP1A2CYP2C19ITGB3ITGA2B | |
| SCHEMBL4364211 | 0.85 | CTSK (0.45) | EPHX1CYP1A2CYP2C19ITGB3ITGA2B | |
| SCHEMBL17175560 | 0.85 | ITGB3 (0.47) | EPHX1ITGB3ITGA2BNOD1 | |
| SCHEMBL9565515 | 0.84 | ECE1 (0.43) | EPHX1ACHESMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL8591688 | 0.84 | ECE1 (0.43) | EPHX1ACHESMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL8872226 | 0.84 | ECE1 (0.43) | EPHX1ACHESMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL4592659 | 0.84 | EPHX1 (0.43) | EPHX1ACHESMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL12640944 | 0.84 | EPHX1 (0.43) | EPHX1ACHESMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL480292 | 0.83 | EPHX1 (0.46) | EPHX1ACHESMN1; SMN2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
| WO-2016106241-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-2459557-A1 | CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | EPHX1 3957/4885ACHE 3437/4885SMN1; SMN2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.